Category: 721401-43-0

Evison, Benny J.; Palmer, James T.; Lambert, Gilles; Treutlein, Herbert; Zeng, Jun; Nativel, Brice; Chemello, Kevin; Zhu, Qing; Wang, Jie; Teng, Yanfen; Tang, Wei; Xu, Yanfeng; Rathi, Anuj Kumar; Kumar, Sanjay; Suchowerska, Alexandra K.; Parmar, Jasneet; Dixon, Ian; Kelly, Graham E.; Bonnar, James published the artcile< A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove>, Safety of Isoquinolin-8-ylboronic acid, the main research area is cardiovascular disease PCSK9 LDL receptor cholesterol mall moleculep; Cardiovascular disease; LDL cholesterol; LDL receptor; Low density lipoprotein (LDL); Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9); Small molecule.

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low d. lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small mol. inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavorable for binding by small organic mols. Despite its challenging nature, we report herein the discovery of compound 3f as a small mol. inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chem., 3f emerged as a lead-like mol. by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered s.c. in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small mol. inhibitor against PCSK9 is therapeutically viable.

Bioorganic & Medicinal Chemistry published new progress about Bioavailability. 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Safety of Isoquinolin-8-ylboronic acid.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Chilamari, Maheshwerreddy; Immel, Jacob R.; Bloom, Steven published the artcile< General Access to C-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media>, Safety of Isoquinolin-8-ylboronic acid, the main research area is radical preparation photocatalyzed oxidation boronic acid catalyst reaction mechanism; conjugate addition reaction radical Michael acceptor.

Carbon-centered radicals are indispensable building blocks for modern synthetic chem. In recent years, visible light photoredox catalysis has become a promising avenue to access C-centered radicals from a broad array of latent functional groups, including boronic acids. Herein, we present an aqueous protocol wherein water features a starring role to help transform aliphatic, aromatic, and heteroaromatic boronic acids to C-centered radicals with a bioinspired flavin photocatalyst. These radicals are used to deliver a diverse pool of alkylated products, including three pharmaceutically relevant compounds, via open-shell conjugate addition to disparate Michael acceptors. The mechanism of the reaction is investigated by computational studies, deuterium labeling, radical-trapping experiments, and spectroscopic anal.

ACS Catalysis published new progress about Alkylation (deborylative-alkylation). 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Safety of Isoquinolin-8-ylboronic acid.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Evison, Benny J.; Palmer, James T.; Lambert, Gilles; Treutlein, Herbert; Zeng, Jun; Nativel, Brice; Chemello, Kevin; Zhu, Qing; Wang, Jie; Teng, Yanfen; Tang, Wei; Xu, Yanfeng; Rathi, Anuj Kumar; Kumar, Sanjay; Suchowerska, Alexandra K.; Parmar, Jasneet; Dixon, Ian; Kelly, Graham E.; Bonnar, James published the artcile< A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove>, Application In Synthesis of 721401-43-0, the main research area is cardiovascular disease PCSK9 LDL receptor cholesterol mall moleculep; Cardiovascular disease; LDL cholesterol; LDL receptor; Low density lipoprotein (LDL); Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9); Small molecule.

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low d. lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small mol. inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavorable for binding by small organic mols. Despite its challenging nature, we report herein the discovery of compound 3f as a small mol. inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chem., 3f emerged as a lead-like mol. by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered s.c. in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small mol. inhibitor against PCSK9 is therapeutically viable.

Bioorganic & Medicinal Chemistry published new progress about Bioavailability. 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Application In Synthesis of 721401-43-0.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Montgomery, Deanna; Anand, Jessica P.; Baber, Mason A.; Twarozynski, Jack J.; Hartman, Joshua G.; Delong, Lennon J.; Traynor, John R.; Mosberg, Henry I. published the artcile< Structure-activity relationships of 7-substituted dimethyltyrosine-tetrahydroisoquinoline opioid peptidomimetics>, Reference of 721401-43-0, the main research area is dimethyltyrosine tetrahydroisoquinoline opioid peptidomimetic structure activity; multifunctional ligands; opioids; peptidomimetic; structure-activity.

The opioid receptors modulate a variety of biol. functions, including pain, mood, and reward. As a result, opioid ligands are being explored as potential therapeutics for a variety of indications. Multifunctional opioid ligands, which act simultaneously at more than one type of opioid receptor, show promise for use in the treatment of addiction, pain, and other conditions. Previously, we reported the creation of bifunctional kappa opioid receptor (KOR) agonist/mu opioid receptor (MOR) partial agonist ligands from the classically delta opioid receptor (DOR) antagonist selective dimethyltyrosine-tetrahydroisoquinoline (Dmt-Tiq) scaffold through the addition of a 7-benzyl pendant on the tetrahydroisoquinoline ring. This study further explores the structure-activity relationships surrounding 7-position pendants on the Dmt-Tiq scaffold. Some analogs maintain a KOR agonist/MOR partial agonist profile, which is being explored in the development of a treatment for cocaine addiction. Others display a MOR agonist/DOR antagonist profile, which has potential to be used in the creation of a less addictive pain medication. Ultimately, we report the synthesis and in vitro evaluation of novel opioid ligands with a variety of multifunctional profiles.

Molecules published new progress about Cell membrane. 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Reference of 721401-43-0.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Ni, Nanting; Laughlin, Sarah; Wang, Yingji; Feng, You; Zheng, Yujun; Wang, Binghe published the artcile< Probing the general time scale question of boronic acid binding with sugars in aqueous solution at physiological pH>, Product Details of C9H8BNO2, the main research area is boronate sugar carbohydrate.

The boronic acid group is widely used in chemosensor design due to its ability to reversibly bind diol-containing compounds The thermodn. properties of the boronic acid-diol binding process have been investigated extensively. However, there are few studies of the kinetic properties of such binding processes. In this report, stopped-flow method was used for the first time to study the kinetic properties of the binding between three model arylboronic acids, 4-, 5-, and 8-isoquinolinylboronic acids, and various sugars. With all the boronic acid-diol pairs examined, reactions were complete within seconds. The kon values with various sugars follow the order of D-fructose > D-tagatose > D-mannose > D-glucose. This trend tracks the thermodn. binding affinities for these sugars and demonstrates that the ‘on’ rate is the key factor determining the binding constant

Bioorganic & Medicinal Chemistrypublished new progress about Boronic acids Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Product Details of C9H8BNO2.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem